NO953093L - Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler - Google Patents

Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler

Info

Publication number
NO953093L
NO953093L NO953093A NO953093A NO953093L NO 953093 L NO953093 L NO 953093L NO 953093 A NO953093 A NO 953093A NO 953093 A NO953093 A NO 953093A NO 953093 L NO953093 L NO 953093L
Authority
NO
Norway
Prior art keywords
compounds
calcium antagonist
antioxidant activity
antioxidant
protective agents
Prior art date
Application number
NO953093A
Other languages
English (en)
Norwegian (no)
Other versions
NO953093D0 (no
Inventor
Mark Hellberg
George Barnes
Jr Robert J Collier
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of NO953093D0 publication Critical patent/NO953093D0/no
Publication of NO953093L publication Critical patent/NO953093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO953093A 1993-12-08 1995-08-07 Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler NO953093L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16398093A 1993-12-08 1993-12-08
PCT/US1994/014069 WO1995015958A1 (en) 1993-12-08 1994-12-07 Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents

Publications (2)

Publication Number Publication Date
NO953093D0 NO953093D0 (no) 1995-08-07
NO953093L true NO953093L (no) 1995-10-09

Family

ID=22592463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953093A NO953093L (no) 1993-12-08 1995-08-07 Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler

Country Status (17)

Country Link
US (1) US5646149A (ko)
EP (1) EP0682664B1 (ko)
JP (1) JP3150155B2 (ko)
KR (1) KR960701033A (ko)
CN (1) CN1100774C (ko)
AT (1) ATE199716T1 (ko)
BR (1) BR9406080A (ko)
CA (1) CA2153979C (ko)
DE (1) DE69426871T2 (ko)
DK (1) DK0682664T3 (ko)
ES (1) ES2156934T3 (ko)
FI (1) FI953748A0 (ko)
GR (1) GR3035971T3 (ko)
HK (1) HK1011685A1 (ko)
NO (1) NO953093L (ko)
PT (1) PT682664E (ko)
WO (1) WO1995015958A1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034299A1 (en) * 1994-06-10 1995-12-21 Telor Ophthalmic Pharmaceuticals, Inc. Inhibition of intraoperative miosis/production of mydriasis by calcium channel blockers
US5719167A (en) * 1995-08-07 1998-02-17 Alcon Laboratories, Inc. Angiostatic compounds
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US6271224B1 (en) 1995-12-21 2001-08-07 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
DK0842165T3 (da) * 1996-03-25 2001-08-06 Alcon Lab Inc Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
JP3562903B2 (ja) * 1996-05-31 2004-09-08 セイコープレシジョン株式会社 フォーカルプレーンシャッタ
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6943168B2 (en) * 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
WO2004089922A2 (en) * 1998-06-30 2004-10-21 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
WO2001041756A2 (en) * 1999-12-02 2001-06-14 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
WO2001046166A2 (en) 1999-12-20 2001-06-28 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US20030199523A1 (en) * 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
MXPA05012899A (es) * 2003-05-30 2006-06-23 Neuromed Tech Inc 3-aminometil-pirrolidinas como bloqueadores del canal de calcio tipo n.
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
AU2005231872A1 (en) * 2004-04-09 2005-10-20 Neuromed Pharmaceuticals Ltd. Diarylamine derivatives as calcium channel blockers
WO2006024160A1 (en) * 2004-08-30 2006-03-09 Neuromed Pharmaceuticals Ltd. Urea derivatives as calcium channel blockers
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
EP1976841A4 (en) * 2005-12-19 2010-07-28 Neuromed Pharmaceuticals Ltd HETEROCYCLIC AMIDDERIVES AS CALCIUM CHANNEL BLOCKERS
CA2643924A1 (en) * 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
EP2019676A2 (en) * 2006-05-11 2009-02-04 Neuromed Pharmaceuticals, Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US20100029681A1 (en) * 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
US20100168103A1 (en) * 2006-09-14 2010-07-01 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
EP2074105A4 (en) * 2006-10-13 2010-10-06 Neuromed Pharmaceuticals Ltd CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB705979A (en) * 1951-03-22 1954-03-24 Henri Morren 1.4-aralkyl piperazines and process for the preparation thereof
BE790971A (fr) * 1971-11-09 1973-05-07 Janssen Pharmaceutica Nv Metode ter voorkoming van patologische reakties die de funktie van het komplement vereisen
NL7306771A (ko) * 1972-06-02 1973-12-04
DE2900810A1 (de) * 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
IT1213131B (it) * 1984-02-02 1989-12-14 Yason Srl Composto ad attivita' calcio antagonista periferica, anticonvulsivante ed eumetabolica cerebrale,metodo per la sua preparazione e composizioni farmaceutiche.
JPS60222472A (ja) * 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
WO1987005020A1 (en) * 1986-02-21 1987-08-27 Kuraray Co., Ltd. 3,4-dihydro-2h-benzopyran derivatives and their medicinal use
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
EP0487510A1 (en) * 1987-04-27 1992-05-27 The Upjohn Company Pharmaceutically active amines
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US5120843A (en) * 1987-04-27 1992-06-09 Upjohn Pharmaceutically active amines
WO1989005803A1 (en) * 1987-12-24 1989-06-29 Kuraray Co., Ltd. 3,4-dihydro-2h-1,3-benzoxazine derivatives and their medicinal use
US5015661A (en) * 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
EP0369082A1 (en) * 1988-11-14 1990-05-23 Merrell Dow Pharmaceuticals Inc. Cardioprotective tocopherol analogs
TW199152B (ko) * 1990-11-01 1993-02-01 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
ATE199716T1 (de) 2001-03-15
EP0682664B1 (en) 2001-03-14
BR9406080A (pt) 1996-02-06
DK0682664T3 (da) 2001-07-16
NO953093D0 (no) 1995-08-07
DE69426871D1 (de) 2001-04-19
AU697050B2 (en) 1998-09-24
WO1995015958A1 (en) 1995-06-15
AU1336895A (en) 1995-06-27
HK1011685A1 (en) 1999-07-16
GR3035971T3 (en) 2001-08-31
DE69426871T2 (de) 2001-06-21
EP0682664A1 (en) 1995-11-22
JPH08507546A (ja) 1996-08-13
US5646149A (en) 1997-07-08
FI953748A (fi) 1995-08-07
ES2156934T3 (es) 2001-08-01
CA2153979A1 (en) 1995-06-15
FI953748A0 (fi) 1995-08-07
CA2153979C (en) 2003-10-21
JP3150155B2 (ja) 2001-03-26
CN1100774C (zh) 2003-02-05
PT682664E (pt) 2001-06-29
CN1117292A (zh) 1996-02-21
KR960701033A (ko) 1996-02-24

Similar Documents

Publication Publication Date Title
NO953093L (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
ES2115163T3 (es) Procedimiento para inhibir la proliferacion de celulas de musculos lisos y la restinosis.
ATE204857T1 (de) Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
DE69430465D1 (de) Hemmung uteriner Fibrose
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
ES520860A0 (es) Procedimiento de preparar teofilinas 7-substituidas.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
NO20010654D0 (no) Ny anvendelse av taxoidderivater
FI934680A (fi) Arylmorfolin, framstaellning och anvaending
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
MX9701327A (es) Metodos para inhibir el cancer endometrial.
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
EA199800678A1 (ru) Способ ингибирования мышечно-апоневротических фиброматозов (десмоидных опухолей)
DK0772438T3 (da) Anvendelse af benzothiophener til fremstilling af et medikament til reduktion af ardannelse under sårheling
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9806036A (es) Compuestos para inhibir tumores en el colon.
NO973470L (no) Fremgangsmåte for minsking av serumkalsiumnivåer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application